Tag: Market
RSV Prophylactic Beyfortus: Potential Competitors and Market Trends
Alnylam Pharmaceuticals, led by CEO Yvonne Greenstreet, is making strides in expanding the use of its RNA-based gene-silencing heart drug, vutrisiran. The drug has...
BREAKING NEWS
Bluebird Bio Sold to Carlyle, SK Capital for Under $30M
Bluebird Bio, a once-promising biotech company, made headlines recently with its decision to sell itself and its portfolio of gene therapies to investment firms...
